

Introduction: Lung cancer is one of the most prevalent cancers worldwide. Dickkopf-1 (DKK-1) and -2 (DKK-2) are important proteins for the regulated Wnt signalling pathway. Alterations in the Wnt pathway are associated with tumour progression. The aim of the study was to analyse the concentration of DKK-1 and DKK-2 in tumour and matched non-tumour (NT) samples of 65 patients with non-small cell lung cancer (NSCLC), including 3 subtypes: adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell carcinoma (LCC).

Material and methods: The protein concentration was measured by enzyme-linked immunosorbent assay (ELISA) in homogenates.

Results: The difference between the level of DKK-1 in tumour and NT specimens was not significant for the whole NSCLC group and SCC and LCC subtype, while in AC samples they were significantly higher ($p = 0.028$). The highest concentration of DKK-1 was found in the advanced NSCLC samples, with the T4 parameter as well as stage III. Significantly decreased DKK-2 concentrations were detected in all NSCLC subtypes ($p < 0.05$). Moreover, the DKK-2 level was higher in non-smokers than in smokers. The results indicate that concentrations of DKKs were different in relation to subtypes as well as clinical and socio-demographic parameters. The concentration of DKKs could be associated with the progression of NSCLC.

Conclusions: We suggest that DKK-1 could play an oncogenic role in AC, while DKK-2 could be a tumour suppressor in all NSCLC subtypes. Dickkopf-1 and DKK-2 proteins could have differential roles in the Wnt signalling pathway, which is important in many cellular processes, such as proliferation and apoptosis.

Key words: non-small cell lung cancer (NSCLC), Dickkopf-1 (DKK-1), Dickkopf-2 (DKK-2), adenocarcinoma (AC), squamous cell carcinoma (SCC), large cell carcinoma (LCC), protein concentration.

Contemp Oncol (Pozn) 2024; 28 (1): 9–14
DOI: <https://doi.org/10.5114/wo.2024.136981>

The assessment of Dickkopf-1 and Dickkopf-2 protein concentration in different subtypes of non-small cell lung cancer subtypes

Dorota Hudy¹, Jadwiga Gaździcka¹, Agata Świętek¹, Karolina Gołąbek¹, Mateusz Rydel², Damian Czyżewski², Joanna Katarzyna Strzelczyk¹

¹Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland

²Department of Thoracic Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland

Introduction

In 2020, lung cancer was the second most diagnosed cancer worldwide and the leading cause of death [1]. The 5-year relative survival increased in recent decades, but it remains below 26% [2, 3]. The risk of the disease increases with age and history of smoking [4]. Other risk factors include occupational exposure to asbestos, certain metals, silica, and ionising radiation. In addition, certain chronic respiratory diseases (chronic obstructive pulmonary disease, pulmonary fibrosis, pneumoconiosis, tuberculosis) increase the risk of lung cancer [5, 6].

Wnt is one of the pathways of intracellular signal transduction and is involved in such processes as cell differentiation and proliferation, apoptosis, migration, and invasion. It is regulated by binding of the Wnt ligands to the FZD and LRP-5-6 receptors [7]. Dickkopf-1 (DKK-1) and -2 (DKK-2) belong to the DKK family of proteins, which inhibit the Wnt/ β -catenin pathway by binding to LPR5/6 receptors [7, 8]. Changes in activity of the Wnt pathway and associated disturbances in the expression of genes regulated by this signalling pathway lead to multiple pathologies, including cancer [9]. Dickkopf-1 and DKK-2 appear to play dual roles as both proto-oncogenes and tumour suppressors [10]. The role of DKK-1 could be associated with the type of tumour. The role of DKK-1 as a tumour suppressor was observed in tumours arising from endoderm and ectoderm, and that of a driver in tumours arising from mesoderm [11]. The role of DKK-2 as a tumour suppressor and antagonist of the Wnt pathway was confirmed in liver cancer [12], while the oncogenic role was proven in prostate cancer [13]. The role of DKK-1 and DKK-2 in non-small cell lung cancer (NSCLC) subtypes remains unclear. Further research is required for a better understanding of the complexity of their molecular mechanisms and the development of new biomarkers useful in the diagnosis and treatment of NSCLC tumourigenesis. The aim of the study was to analyse the DKK-1 and DKK-2 protein concentrations in NSCLC cancer, including the following 3 subtypes: adenocarcinoma (AC), squamous cell carcinoma (SCC), and large cell carcinoma. The level of DKK-1 and DKK-2 was also analysed in connection with the clinical and demographic variables.

Material and methods

Study group and samples

The characteristics of the study group were described in the previous study [14]. The study group was composed of 65 patients with primary NSCLC. The tumour and non-tumour (NT) samples were collected during surgical resection in the Department of Thoracic Surgery, Faculty of Medical Sci-

ences in Zabrze, Medical University of Silesia in Katowice. The main inclusion criteria were patients over 18 years of age with primary NSCLC, who gave informed consent to participate in the study. Patients who gave no consent or had malignancies other than NSCLC were excluded. The non-small cell lung cancer diagnosis was based on CT-guided lung aspiration biopsy. Positron emission tomography/image-based computed tomography (PET/CT) and CT were used to exclude distant metastasis. The endobronchial/endoscopic ultrasound (EBUS/EUS) was used in individuals showing enlarged mediastinal lymph nodes. RO resection was performed in all cases. All samples were classified based on the eighth edition of tumour-node-metastasis (TNM) classification of malignant tumours [15]. The tumour samples were verified histopathologically as NSCLC, while the NT samples were confirmed by a pathologist to be free of cancer cells. Non-tumour samples were obtained at a distance of more than 3 cm from the tumour. This study was approved by the Ethics Committee of the Medical University of Silesia in Katowice (PCN/0022/KB1/72/I/20/21). All specimens were frozen at -75°C until further processing.

Homogenisation

Homogenisation was performed according to the methodology described in the previous studies [14, 16]. The samples of the tumour and NT were weighed and homogenised using a PRO200 homogeniser (PRO Scientific Inc., Oxford, CT, USA) at 10,000 rpm in 9 volumes of PBS (EURx, Gdansk, Poland). After homogenisation, sonification with an ultrasonic cell disrupter was performed (UPI00H, Hielscher Ultrasonics GmbH, Teltow, BB, Germany).

Total protein measurement and concentrations of Dickkopf-1 and Dickkopf-2

The measurement of total protein was performed according to the methodology described in previous studies [14, 16]. An AccuOrange™ Protein Quantitation Kit (BioTium, Fremont, CA, USA) was used to determine the total protein concentration according to the manufacturers' instruction. The detection range was 0.1–15 $\mu\text{g}/\text{ml}$. A Synergy H1 microplate reader (BioTek, Winooski, VT, USA) was used to assess the fluorescence at excitation and emission wavelengths of 480 and 598 nm, respectively. The enzyme-linked immunosorbent assay (ELISA) was used to assess the levels of the proteins following the manufacturers' instructions. The Dickkopf-1 levels were evaluated by a Dickkopf-Related Protein 1 ELISA Kit (Cloud-Clone Corp. Houston, TX, USA; product No. SEA741Hu) with a sensitivity of 0.059 ng/ml. The concentration of DKK-2 was measured with an ELISA Kit for Dickkopf Related Protein 2 (Cloud-Clone Corp. Houston, TX, USA; product No. SEB033Hu) with a sensitivity of 28 pg/ml. For both kits the intra-assay and inter-assay were < 10% and < 12%, respectively. 100 μl of 20 \times diluted DKK-1 homogenates and 100 μl undiluted DKK-2 homogenates were used for assay. The absorbance of the samples was determined using a Synergy H1 microplate reader (BioTek, Winooski, VT,

USA). The measurement was conducted at the wavelength of 450 nm. The results were obtained with Gen5 2.06 software (BioTek, Winooski, VT, USA). The levels of proteins were normalised to the corresponding total protein level and presented as ng/ μg for DKK-1 and pg/ μg for DKK-2.

Statistical analyses

The normality of the data was tested using the Shapiro-Wilk test. Results are presented as median with lower and upper quartiles. Student's *t*-test and the Mann-Whitney *U* test were used to verify the significance of differences in means or medians between the groups. To compare the tumour and the NT levels, a paired Student's *t*-test was performed. The correlations between the examined variables were determined with Spearman's rank correlation coefficient. $P < 0.05$ was assumed as statistically significant. The statistical analysis was performed using STATISTICA 13.1 software (TIBCO Software Inc., Palo Alto, CA, USA).

Results

Study group

The study group was composed of 65 NSCLC patients (mean age 69.09 ± 7.13 years), with 26 (40%) women and 39 (60%) men. Thirty-one (65.96%) cases were current smokers, 16 (34.04%) were former smokers, and 8 (12.31%) were non-smokers. No information on smoking habits was collected from 10 (15.38%) patients. The non-small cell lung cancer patients included 28 (43.08%) with AC, 23 (35.38%) with SCC, and 14 (21.54%) with large cell carcinoma. The clinical characteristics of the study group are presented in Table 1.

Dickkopf-1 and Dickkopf-2 protein levels in non-small cell lung cancer patients

No significant differences were found in the DKK-1 levels in NSCLC tumours compared to NT samples. Analysis of NSCLC subtypes found significantly higher levels of DKK-1 in AC tumours as compared to AC NT samples ($p = 0.028$). We found that the DKK-2 concentration was significantly lower in tumour samples of NSCLC and all NSCLC subtypes as compared to NT samples. The results are presented in Table 2.

The concentration of selected Dickkopf proteins among non-small cell lung cancer subtypes

The comparison of selected DKK protein concentrations among NSCLC subtypes showed that the difference in DKK-1 level in tumour samples was not significant between all subtypes (AC vs. SCC, $p = 0.768$; AC vs. large cell carcinoma [LCC] $p = 0.360$; SCC vs. LCC $p = 0.383$). However, in NT samples, the concentration of DKK-1 was significantly lower in AC compared to SCC and LCC (AC vs. SCC, $p = 0.045$; AC vs. LCC $p = 0.005$).

Lower DKK-2 concentrations were found in tumour samples collected from AC patients than in LCC cases ($p = 0.045$). In NT samples, a lower DKK-2 level was observed in AC cases compared to LCC ($p = 0.014$) and SCC ($p = 0.016$). The results are presented in Figure 1 and 2.

The concentration of selected Dickkopf proteins and sociodemographic and clinicopathological parameters

In the NSCLC subtype group, there were too few patients to analyse the concentration of DKK-1 and DKK-2 according to clinicopathological and socio-demographic parameters. Therefore, we conducted this analysis in the NSCLC group undivided by histological subtypes.

The Dickkopf-1 concentration in the tumour samples was highest in the patients with clinical stage T4 and statistically higher than in patients with T2 (27.14 vs. 6.06; $p = 0.048$). The results are presented in Figure 3. Moreover, patients with stage III NSCLC showed significantly higher levels of DKK-1 protein in the tumour samples than patients with stage I NSCLC (12.62 vs. 6.04; $p = 0.033$), which is presented in Figure 4. No other significant differences were found between the concentrations of selected DKK proteins and the socio-demographic or clinical pathological parameters. However, the median concentration of DKK-1 was insignificantly higher in non-smokers compared to smokers (current and former) in tumour samples (non-smoker 9.02 vs. smoker 6.83; current smoker: 5.92; former smokers: 8.65) and in NT samples (non-smoker 8.54 vs. smoker 6.51; current smoker: 6.51; former smokers: 6.17).

Significantly higher DKK-2 concentrations were found in tumour samples obtained from patients with pleural invasion PL2, compared to PL1 (215.54 vs. 123.13; $p = 0.042$). The results are presented in Figure 5. We observed higher DKK-2 levels in the tumour samples from NSCLC patients who had never smoked compared to current smokers (185.29 vs. 91.84; $p = 0.020$). Similarly, in NT samples, the concentration of DKK-2 was significantly higher in patients who had never smoked compared to current smokers (873.99 vs. 252.66; $p = 0.036$), also when compared to the overall status of a smoker (current + former smoker) (873.99 vs. 315.82; $p = 0.042$). We observed no other statistically significant differences between the DKK-2 concentration and sociodemographic or clinicopathological parameters.

Our study found a positive correlation between the concentration of DKK-1 and DKK-2 in tumour samples ($p < 0.001$, $r_s = 0.548$). A similar positive correlation was observed in non-cancer samples ($p < 0.001$, $r_s = 0.665$). In

Table 1. Clinical characteristics of the study group

Parameters	Total NSCLC, N (%)
T classification	
T1	7 (10.77)
T2	38 (58.46)
T3	12 (18.46)
T4	8 (12.31)
Nodal status	
N0	53 (81.54)
N1	11 (16.92)
N2	1 (1.54)
N3	0 (0.00)
Stage	
I	32 (49.23)
II	20 (30.77)
III	13 (20.00)
Histological grading	
G1	2 (3.07)
G2	16 (24.62)
G3	38 (58.46)
NA	9 (13.85)
Pleural invasion	
PL0	37 (56.92)
PL1	10 (15.38)
PL2	8 (12.31)
NA	10 (15.38)

NA – no assessment, NSCLC – non-small cell lung cancer

addition, the level of DKK-2 in NSCLC specimens was positively correlated with DKK-2 concentration in non-cancer samples ($p = 0.004$, $r_s = 0.398$).

Discussion

The role of DKK-1 and DKK-2 in NSCLC progression remains unclear. Based on our knowledge, this has been

Table 2. Dickkopf-1 and Dickkopf-2 levels in tumour and non-tumour samples in the non-small cell lung cancer group, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma

Parameters	Protein concentration						
	Samples	DKK-1[ng/μg]			p-value	DKK-2 [pg/ μg]	
Median		Q1–Q3		Median		Q1–Q3	p-value
NSCLC	Tumour	6.59	4.11–14.29	0.262	146.96	76.38–300.99	< 0.001
	Non-tumour	6.51	3.63–9.05		363.01	159.69–671.10	
AC	Tumour	7.44	5.27–10.90	0.028	93.15	64.92–185.29	0.034
	Non-tumour	4.85	3.21–6.69		205.13	102.71–461.89	
SCC	Tumour	5.84	3.13–14.30	0.874	120.01	72.41–440.45	0.004
	Non-tumour	6.83	4.55–9.26		567.27	252.66–741.52	
LCC	Tumour	10.90	4.54–24.78	0.665	216.98	128.09–301.45	0.007
	Non-tumour	8.91	6.49–10.66		521.54	259.49–907.29	

AC – adenocarcinoma, LCC – large cell carcinoma, NSCLC – non-small cell lung cancer, SCC – squamous cell carcinoma




Fig. 1. Dickkopf-2 level in tumour samples according to non-small cell lung cancer subtype

Results are presented as box plots with the median in the middle and Q1–Q3 as the box borders where whiskers indicate max and min values; p-values below 0.05 indicated significant differences between groups.

AC – adenocarcinoma, DKK-2 – Dickkopf-2, LCC – large cell carcinoma, SCC – squamous cell carcinoma




Fig. 2. Dickkopf-2 level in non-tumour samples according to non-small cell lung cancer subtype

Results are presented as box plots with the median in the middle and Q1–Q3 as the box borders where whiskers indicate max and min values; p-values below 0.05 indicated significant differences between groups.

AC – adenocarcinoma, DKK-2 – Dickkopf-2, LCC – large cell carcinoma, SCC – squamous cell carcinoma




Fig. 3. Dickkopf-1 level in tumour samples according to T classification

Results are presented as box plots with the median in the middle and Q1–Q3 as the box borders where whiskers indicate max and min values; p-values below 0.05 indicated significant differences between groups.




Fig. 4. Dickkopf-1 level in tumour samples according to clinical stage

Results are presented as box plots with the median in the middle and Q1–Q3 as the box borders where whiskers indicate max and min values; p-values below 0.05 indicated significant differences between groups.




Fig. 5. Dickkopf-2 level in tumour samples according to pleural invasion

Results are presented as box plots with the median in the middle and Q1–Q3 as the box borders where whiskers indicate max and min values; p-values below 0.05 indicated significant differences between groups.

the first study to analyse the concentrations of DKK-1 and DKK-2 in tumour and NT samples obtained from patients with NSCLC subtypes.

In the study, the median DKK-1 protein level was insignificantly higher in NSCLC tumours than in NT samples. However, significantly higher levels of DKK-1 protein in tu-

mour samples, compared to NT, were observed in patients with AC. The difference in DKK-1 concentration among NSCLC subtypes was insignificant. On the other hand, we observed that in NT samples, the patients with AC had lower concentrations of DKK-1, compared to LCC and SCC. Some studies found upregulated DKK-1 levels in NSCLC samples, as compared to matched normal tissue by immunohistochemical staging [17–19]. On the other hand, Western blot analysis showed that the DKK-1 protein had a varied level in 10 human NSCLC cell lines [19]. Kim *et al.* reported that the protein level of DKK-1 was different in NSCLC cell lines: upregulated in the AC cell line (A459) and downregulated in the LCC cell line (H460) [20]. Moreover, a study based on AC cell lines observed that decreased concentration of DKK-1 inhibited cell migration and invasion, which confirmed the oncogenic role of NSCLC cell lines [21]. Based on our results, we could hypothesise that patients with AC would have poorer prognosis than those with other NSCLC subtypes. However, further studies are required to verify DKK-1 as a prognostic factor in AC patients. In our study, the highest concentration of DKK-1 was reported in advanced NSCLC samples with T4 and stage III. In the literature, different studies have shown various results. Kimura *et al.* [22] found that DKK-1 levels in patients

with lung AC and SCC were not associated with T and N clinical parameters but were negatively correlated with relapse-free survival [22]. On the other hand, Li *et al.* [17] reported that DKK-1-positive status was correlated with lymph node metastasis and a dismal 5-year survival rate. The authors also analysed the NSCLC cell lines and found that DKK-1 promoted invasion and migration of NSCLC cells [17]. Another study based on NSCLC cell lines and animal models revealed positive association between DKK-1 protein levels and vascular mimicry, confirming the role of DKK-1 in tumour growth, inducing the expression of epithelial-mesenchymal transition-related proteins and tumour cell-associated protein stem cells [23]. Also, Pang *et al.* suggested that DKK-1 played a prominent role in bone metastasis during NSCLC [24]. Interestingly, different DKK-1 levels among NSCLC cell lines were required to modulate the intracellular reactive oxygen species modulator (ROMO1) protein [20]. Kim *et al.* observed that a decreased level of DKK-1 in A459 induced an increase in the ROMO level, followed by cell growth inhibition and loss of epithelial-mesenchymal transition, while upregulated DKK-1 in H460 inhibited cell survival and downregulated the ROMO level [20]. Our results show that the concentration of DKK-1 was changed in tumour progression, which may suggest an oncogenic role in NSCLC.

We reported decreased concentrations of DKK-2 protein in tumour samples of all subtypes of NSCLC, compared to NT samples. Comparing NSCLC subtypes, we found that the median DKK-2 concentration was lowest in AC: significantly lower than in LCC in tumour samples, and lower than SCC and LCC in normal tissue samples. To our knowledge, this observation has not been reported before. The literature points to the dual role of DKK-2 in cancerogenesis. Based on our knowledge, only a few studies analysed the DKK-2 level in NSCLC. Song *et al.* found reduced mRNA *DKK-2* by Rho GTPase-activating protein 9 (ARHGAP9) in lung AC tumour samples compared to healthy lung tissue. Moreover, the concentration of DKK-2 was reduced in the lung AC cell line that activated the Wnt/ β -catenin pathway [25]. Additionally, Zhang *et al.* reported the role of DKK-2 as an antagonist Wnt signalling pathway [26]. The authors observed that DKK-2 was directly targeted by miR-657, and a decreased level of DKK-1 was associated with TNM stage, differentiation, and lymph node metastasis in NSCLC patients [26]. The tumour suppressor role of DKK-2 in inhibiting cell proliferation and inducing apoptosis was reported in breast cancer [27] and renal cell carcinoma [28]. Furthermore, reduced DKK-2 protein level was noticed in hepatocellular carcinoma [29], while decreased mRNA *DKK-2* by promoter methylation was found in breast cancer [27], cervical cancer [30], and colorectal cancer [31]. On the other hand, the negative role of DKK-2 was shown in colorectal cancer, where the upregulated level of this protein in tumour samples was associated with metastasis and angiogenesis [32], while in prostate cancer cell lines it promoted cell proliferation [33]. Additionally, an increased DKK-2 protein level was observed in tumour tissue of the pancreatic AC, which suggested that higher concentration of this protein could be a tool secreted by tumour cells to modulate immune status [34]. Based on our results, we suggested that DKK-2 was a tumour sup-

pressor in NSCLC. Moreover, we hypothesised that patients with AC could have poorer prognosis than patients with LCC or SCC. However, further studies are needed to verify this hypothesis.

Our study reported that smokers had a significantly decreased concentration of DKK-2, while non-smokers showed insignificantly higher median levels of DKK-1. Moreover, we observed that DKK-1 and DKK-2 had higher levels in tumour samples obtained from former smokers than in those from current smokers. The study based on a lung cancer cell line showed that tobacco smoke exposure induces polycomb-mediated repression of DKK-1, and withdrawal of tobacco smoke from culture media effects re-expression of the DKK-1 [35]. It appears that the use of stimulants may impact protein levels and influence the development of cancer.

The main limitation of our study was the small size of samples. Moreover, we have not yet collected enough data to verify the survival rate. However, we plan to analyse the correlation between the concentration and the survival rate for patients with NSCLC. The impact of the analysed proteins may be important for the prognosis of patients with specific subtypes of non-small cell lung cancer.

Conclusions

We conclude that the DKK-1 level was increased in advanced NSCLC, and it might play an oncogenic role in lung AC. On the other hand, our results suggested that DKK-2 could play a tumour suppressor role in subtypes of NSCLC, including AC, SCC, and large cell carcinoma. Moreover, the significant differences in DKK-1 and DKK-2 concentrations between tumour and NT samples in patients with AC could suggest a worse prognosis for this NSCLC subtype. However, further studies are needed to verify this hypothesis and determine the prognostic values of DKK-1 and DKK-2 for NSCLC patients.

Disclosures

1. This research was funded by the Medical University of Silesia PCN-1-113/N/2/O.
2. Assistance with the article: None.
3. Financial support and sponsorship: None.
4. Conflicts of interest: None.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021; 71: 209-249.
2. Lu T, Yang X, Huang Y, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. *Cancer Manag Res* 2019; 11: 943-953.
3. Cancer Stat Facts: Lung and Bronchus Cancer. Available from: <https://seer.cancer.gov/statfacts/html/lungb.html> (accessed: 20.10.2023).
4. Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-based lung cancer screening: a systematic review. *Lung Cancer* 2020; 147: 154-186.
5. Corrales L, Rosell R, Cardona AF, Martín C, Zatarain-Barrón ZL, Arieta O. Lung cancer in never smokers: the role of different risk factors other than tobacco smoking. *Crit Rev Oncol Hematol* 2020; 148: 102895.

6. Dubin S, Griffin D. Lung cancer in non-smokers. *Mo Med* 2020; 117: 375-379.
7. Zhang Y, Wang X. Targeting the Wnt/ β -catenin signaling pathway in cancer. *J Hematol Oncol* 2020; 13: 165.
8. Baetta R, Banfi C. DKK (Dickkopf) proteins. *Arterioscler Thromb Vasc Biol* 2019; 39: 1330-1342.
9. Duchartre Y, Kim YM, Kahn M. The Wnt signaling pathway in cancer. *Crit Rev Oncol Hematol* 2016; 99: 141-149.
10. Giralt I, Gallo-Oller G, Navarro N, et al. Dickkopf proteins and their role in cancer: a family of Wnt antagonists with a dual role. *Pharmaceuticals* 2021; 14: 810.
11. Doucet D, Brubaker C, Turner D, Gregory CA. Factors affecting the role of canonical Wnt inhibitor Dickkopf-1 in cancer progression. *Front Oncol* 2023; 13: 1114822.
12. Lin YF, Li LH, Lin CH, et al. Selective retention of an inactive allele of the DKK2 tumor suppressor gene in hepatocellular carcinoma. *PLoS Genet* 2016; 12: e1006051.
13. Xu W, Pang K, Zhou ZG, et al. Dickkopf 2 promotes proliferation and invasion via Wnt signaling in prostate cancer. *Mol Med Rep* 2016; 14: 2283-2288.
14. Gaździcka J, Świętek A, Hudy D, et al. Concentration of secreted frizzled-related proteins (SFRPs) in non-small cell lung carcinoma subtypes – a preliminary study. *Curr Oncol* 2023; 30: 9968-9980.
15. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Hoboken NJ: Wiley-Blackwell, Oxford, UK 2017.
16. Świętek A, Gotąbek K, Hudy D, et al. The potential association between E2F2, MDM2 and p16 protein concentration and selected sociodemographic and clinicopathological characteristics of patients with oral squamous cell carcinoma. *Curr Issues Mol Biol* 2023; 45: 3268-3278.
17. Li S, Qin X, Guo X, et al. Dickkopf-1 is oncogenic and involved in invasive growth in non small cell lung cancer. *PLoS One* 2013; 8: e84944.
18. Zhang Q, Zhao M, Lin S, et al. Prediction of prognosis and immunotherapy response in lung adenocarcinoma based on CD79A, DKK1 and VEGFC. *Heliyon* 2023; 9: e18503.
19. Xiang XJ, Liu YW, Chen DD, Yu S. Differential expression of Dickkopf-1 among non-small cell lung cancer cells. *Mol Med Rep* 2015; 12: 1935-1940.
20. Kim IG, Kim SY, Kim HA, et al. Disturbance of DKK1 level is partly involved in survival of lung cancer cells via regulation of ROMO1 and γ -radiation sensitivity. *Biochem Biophys Res Commun* 2014; 443: 49-55.
21. Zhang J, Zhang X, Zhao X, et al. DKK1 promotes migration and invasion of non-small cell lung cancer via β -catenin signaling pathway. *Tumor Biol* 2017; 39: 101042831770382.
22. Kimura H, Fumoto K, Shojima K, et al. CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. *J Clin Invest* 2016; 126: 2689-2705.
23. Yao L, Zhang D, Zhao X, et al. Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype. *J Cell Mol Med* 2016; 20: 1673-1685.
24. Pang H, Ma N, Shen W, et al. Effects of DKK1 overexpression on bone metastasis of SBC-3 cells. *Oncol Lett* 2018; 15: 6739-6744.
25. Song W, Wu X, Cheng C, Li D, Chen J, Zhang W. ARHGAP9 knock-down promotes lung adenocarcinoma metastasis by activating Wnt/ β -catenin signaling pathway via suppressing DKK2. *Genomics* 2023; 115: 110684.
26. Zhang Y, Yuan J, Guo M, et al. Upregulation of long intergenic non-coding RNA LINC00326 inhibits non-small cell lung carcinoma progression by blocking Wnt/ β -catenin pathway through modulating the miR-657/dickkopf WNT signaling pathway inhibitor 2 axis. *Biol Direct* 2023; 18: 3.
27. Mu J, Hui T, Shao B, et al. Dickkopf-related protein 2 induces G0/G1 arrest and apoptosis through suppressing Wnt/ β -catenin signaling and is frequently methylated in breast cancer. *Oncotarget* 2017; 8: 39443-39459.
28. Hirata H, Hinoda Y, Nakajima K, et al. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. *Clin Cancer Res* 2009; 15: 5678-5687.
29. Hu Z, Wang P, Lin J, et al. MicroRNA-197 promotes metastasis of hepatocellular carcinoma by activating Wnt/ β -catenin signaling. *Cell Physiol Biochem* 2018; 51: 470-486.
30. Zhang X, Li A, Wu J, et al. Promoter methylation analysis of DKK2 may be a potential biomarker for early detection of cervical cancer. *Asian Biomed* 2022; 16: 181-189.
31. Wang C, Yue Y, Shao B, et al. Dickkopf-related protein 2 is epigenetically inactivated and suppresses colorectal cancer growth and tumor metastasis by antagonizing Wnt/ β -catenin signaling. *Cell Physiol Biochem* 2017; 41: 1709-1724.
32. Deng F, Zhou R, Lin C, et al. Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer. *Theranostics* 2019; 9: 1001-1014.
33. Xu W, Pang K, Zhou ZG, et al. Dickkopf 2 promotes proliferation and invasion via Wnt signaling in prostate cancer. *Mol Med Rep* 2016; 14: 2283-2288.
34. Yang J, Jiang Y, He R, et al. DKK2 impairs tumor immunity infiltration and correlates with poor prognosis in pancreatic ductal adenocarcinoma. *J Immunol Res* 2019; 2019: 1-12.
35. Hussain M, Rao M, Humphries AE, et al. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. *Cancer Res* 2009; 69: 3570-3578.

Address for correspondence

Jadwiga Gaździcka

Department of Medical and Molecular Biology
Faculty of Medical Sciences in Zabrze
Medical University of Silesia in Katowice
19 Jordana St.
41-808 Zabrze, Poland
e-mail: jgadzicka@sum.edu.pl

Submitted: 15.01.2024

Accepted: 02.03.2024